Board of Directors
The Vertex Board of Directors is a diverse and highly trained group of professionals who bring unique experience in business, scientific and civic leadership. Our Board has been a source of stability and experience as Vertex has grown from a small research startup to a global S&P 500 company that has launched three breakthrough medicines in four years.
Over time, the Board has evolved to meet Vertex’s needs and help the company achieve our future goals. Moving forward, our Board will continue to play a critical role in helping Vertex successfully transition into a sustainably profitable company for the first time in our history.
Jeffrey Leiden, M.D., Ph.D.
Chairman, President and CEO
Dr. Leiden is the Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals. He has served as a member of Vertex's board of directors since 2009. Dr. Leiden has more than 20 years of scientific, commercial and financial experience in the pharmaceutical and biotechnology industries as well as clinical and scientific experience in academia as a practicing cardiologist and molecular biologist. Read more
Prior to joining Vertex, Dr. Leiden was a Managing Director for Clarus Ventures, a life sciences venture capital firm he joined in 2006. From 2000 to 2006, he served as President and Chief Operating Officer, and Chief Scientific Officer, at Abbott Laboratories where he had responsibility for running Abbott’s global pharmaceuticals business. While at Abbott, Dr. Leiden helped launch multiple breakthrough medicines, including Humira for rheumatoid arthritis and other autoimmune diseases and Kaletra for HIV infection, among others. He also served as a member of the Board of Directors of Abbott Laboratories and TAP from 2001 to 2006.
Dr. Leiden began his career in academia as a practicing cardiologist and molecular biologist. From 1987 to 2000, Dr. Leiden held several academic and hospital appointments, including roles as Chief of Cardiology at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School. During his academic career, Dr. Leiden was also involved in starting several biotechnology companies including Vical and Cardiogene.
Dr. Leiden held a number of board positions in the pharmaceutical and biotechnology industries, including non-executive Vice Chairman for Shire Pharmaceuticals plc and Director of Millennium Pharmaceuticals, Inc. He is a fellow of the American Academy of Arts and Sciences, and an elected member of the Institute of Medicine of the National Academy of Sciences. He is currently the chair of the Scientific Advisory Board for Brigham and Women's Hospital, a trustee of Brigham and Women’s Hospital and a member of the Scientific Advisory Board of Boston Children’s Hospital. Dr. Leiden also serves on the board of directors for the Massachusetts Competitive Partnership (MACP), the Boston Private Industry Council, Massachusetts Mutual Life Insurance Company and Quest Diagnostics, and is the Co-Chair of Massachusetts Governor Deval Patrick's Science, Technology, Engineering and Math (STEM) Advisory Council. Dr. Leiden received his B.A., M.D., and Ph.D. degrees from the University of Chicago.
Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Bhatia joined the Vertex Board in June 2015. She currently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the Massachusetts Institute of Technology’s (MIT) Institute for Medical Engineering and Science and Electrical Engineering and ComputerScience (EECS), where she has worked since 2005. Read more
Dr. Bhatia is also a Biomedical Engineer in the Department of Medicine for Brigham and Women’s Hospital, an investigator for the Howard Hughes Medical Institute, a member of the Koch Institute for Integrative Cancer Research at MIT and a member of the Broad Institute. She has been awarded the Heinz Award for Technology, the Economy, and Employment from the Heinz Family Foundation and the Lemelson-MIT Prize for her dedication to STEM education and improving human health through technological innovations. From 1998 to 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego.
Dr. Bhatia holds a B.S. in Biomedical Engineering from Brown University, an M.S. in Mechanical Engineering and Ph.D. in Biomedical Engineering from MIT, and an M.D. from Harvard Medical School.
Joshua Boger, Ph.D.
Dr. Boger founded Vertex in 1989 and was the company’s Chief Executive Officer from 1992 until May 2009. He served in the additional role of Chairman of the Board from 1997 until 2006. Read more
Dr. Boger began his industry career at Merck in 1978. Immediately before he founded Vertex, he was Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University.
Terrence C. Kearney
Mr. Kearney joined the Vertex Board in May 2011 and has more than three decades of global healthcare experience at major pharmaceutical and life sciences companies. Read more
Mr. Lee joined the Vertex Board in September 2012. He was most recently the Vice President and General Manager of IBM’s Enterprise Marketing Management Group, where he directed a team of nearly 2,000 IBM employees and was a key architect in IBM’s global initiative to serve the needs of Chief Marketing Officers. Read more
Mr. Lee’s team focused on providing solutions to help businesses better understand their customers via social media, mobile behavior and real-time access to consumer information, leveraging analytics to optimize customer communication and engagement.
The Enterprise Marketing Management Group at IBM was formed following the acquisition of Unica in 2010, a recognized leader in marketing software where Mr. Lee was the founder and Chief Executive Officer. Mr. Lee co-founded Unica in 1992, and the company went public in 2005, growing to nearly 600 employees before merging with IBM in 2010. Before co-founding Unica, he held senior positions with Digital Equipment Corporation, the Massachusetts Institute of Technology (MIT) Lincoln Laboratory and the MIT Media Labs. Mr. Lee has served as an Executive in Residence (XIR) and Partner of General Catalyst Partners, a venture capital firm, since April of 2013. Mr. Lee holds a B.S. and M.S. in electrical engineering and computer science from the Massachusetts Institute of Technology and an MBA from Babson College.
Ms. McGlynn joined the Vertex Board in May 2011. She served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 through 2015. Read more
Prior to becoming CEO of IAVI, she served as President, Global Vaccines and Infectious Diseases, for Merck & Co., Inc. In her nearly three decades at Merck, Ms. McGlynn held a number of leadership roles focused on marketing, sales and managed care activities for Merck’s portfolio of medicines. She is a director at Air Products and Amicus Therapeutics, and she is a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.
Ms. McGlynn holds a B.S. in pharmacy and an MBA in marketing from the State University of New York at Buffalo.
Bruce I. Sachs
Mr. Sachs joined the Vertex Board in 1998 and is the Board's co-lead independent director. He brings to Vertex many years of experience working with companies in high-growth business environments as an executive and as a general partner of Charles River Ventures, since 1999. Read more
From 1998 to 1999, he served as Executive Vice President and General Manager of Ascend Communications, Inc. From 1997 until 1998, Mr. Sachs served as President and Chief Executive Officer of Stratus Computer, Inc. From 1995 to 1997, he served as Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. From 1993 to 1995, he served as President and Chief Executive Officer at Xylogics, Inc.
Mr. Sachs holds a bachelor's degree in electrical engineering from Bucknell University, a master's degree in electrical engineering from Cornell University and an MBA from Northeastern University.
Elaine S. Ullian
Ms. Ullian joined the Vertex Board in 1997 and is the Board's co-lead independent director. She brings to Vertex 20 years of experience delivering health care to patients as Chief Executive Officer of major hospitals. Read more
From 1996 to 2010, she served as President and Chief Executive Officer of Boston Medical Center. And from 1994 to 1996, she served as President and Chief Executive Officer of Boston University Medical Center Hospital. From 1987 to 1994, Ms. Ullian served as President and Chief Executive Officer of Faulkner Hospital. She also serves as a director of Hologic, Inc. and Thermo Fisher Scientific Inc.
Ms. Ullian holds a B.A. in political science from Tufts University and an MPH from the University of Michigan.
William Young, Ph.D.
Mr. Young joined the Vertex Board in May 2014 and has extensive experience in leadership roles within major life sciences and pharmaceutical companies. Read more
He spent nearly two decades at Genentech Inc., serving as its Chief Operating Officer from 1997 to 1999, and more recently was Chairman and Chief Executive Officer of Monogram Biosciences, Inc., a provider of molecular diagnostics, from 1999 to 2009. During his time at Genentech, the company launched a number of new medicines for diseases ranging from cystic fibrosis to breast cancer. Mr. Young was the Chairman of the Board of Directors of Biogen Idec from 2010 through June 2014. He has also been the Chairman of NanoString Technologies since 2010 and is a Director for BioMarin Pharmaceutical Inc. and Theravance, Inc. Mr. Young is a venture partner at Clarus Ventures, LLC, a life sciences venture capital firm that he joined in 2010.
Mr. Young earned a B.S. in chemical engineering from Purdue University, an MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993, Mr. Young was elected to the National Academy of Engineering for his contributions to biotechnology.